Did a new drug for kidney transplant patients work better than standard treatment?

Imagine getting a new kidney and hoping the medicine you take will protect it for years. A major five-year study set out to test if a new drug, CFZ533, could do a better job at this than the standard treatment, tacrolimus. The goal was to prevent the terrifying trio: the body rejecting the new organ, losing the kidney graft, or death. The trial involved 418 people who had recently received a transplant or who were already living with one. It was designed to run for a full 60 months, with the first 12 months being critical for the main analysis. However, the study was terminated after an interim look at the data. The abstract does not tell us why it was stopped or what the results showed. It doesn't say whether CFZ533 was more effective, less effective, or had different side effects compared to tacrolimus. All we know is that the planned long-term comparison ended early, leaving the key question about this new treatment's performance unanswered in this public summary.